EVMN insider transaction filings
Evommune, Inc. — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-10. Screen EVMN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-10 | 4 | Carver Kyle — Chief Financial Officer | Purchase (P): 1,000 @ $13.26 | EDGAR |
| 2026-07-08 | 4 | KIRSCH ARTHUR S — Director | Purchase (P): 10,000 @ $13.30 | EDGAR |
| 2026-06-24 | 4 | Patel Jeegar Pravinkumar — Chief Scientific Officer | Option exercise (M): 1,488 @ $3.84 · Sale (S): 1,488 @ $22.50 · Option exercise (M): 1,488 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Drew Janice Suzann — Chief of Dev. Operations | Option exercise (M): 3,839 @ $3.84 · Option exercise (M): 16,161 @ $2.99 · Sale (S): 20,000 @ $22.63 · Option exercise (M): 3,839 (derivative) @ $0 · Option exercise (M): 16,161 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Pena Luis C. — President & CEO, Director | Sale (S): 7,438 @ $22.71 | EDGAR |
| 2026-06-03 | 4 | Patel Jeegar Pravinkumar — Chief Scientific Officer | Option exercise (M): 13,512 @ $3.84 · Sale (S): 16,687 @ $22.74 · Option exercise (M): 13,512 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Pena Luis C. — President & CEO, Director | Sale (S): 16,787 @ $22.74 | EDGAR |
| 2026-06-03 | 4 | Cohen David E — Director | Sale (S): 5,456 @ $20.21 · Sale (S): 600 @ $21.38 · Grant/award (A): 15,673 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | KIRSCH ARTHUR S — Director | Grant/award (A): 15,673 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | MCGRAW BENJAMIN F III — Director | Grant/award (A): 15,673 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Carver Kyle — Chief Financial Officer | Option exercise (M): 15,000 @ $2.99 · Sale (S): 18,175 @ $22.84 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-01 | 4 | Moss Gregory S. — Chief Business & Legal Officer | Option exercise (M): 14,223 @ $1.71 · Sale (S): 14,223 @ $22.83 · Option exercise (M): 14,223 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Patel Jeegar Pravinkumar — Chief Scientific Officer | Grant/award (A): 69,315 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Drew Janice Suzann — Chief of Dev. Operations | Grant/award (A): 73,892 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Carver Kyle — Chief Financial Officer | Grant/award (A): 98,946 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Moss Gregory S. — Chief Business & Legal Officer | Grant/award (A): 115,279 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Bauer Eugene — Chief Medical Officer, Director | Grant/award (A): 51,117 (derivative) @ $0 | EDGAR |
| 2026-04-17 | 4 | Pena Luis C. — President & CEO, Director | Grant/award (A): 291,420 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | LSP 7 Cooperative UA — Director, 10% owner | Grant/award (A): 358,680 @ $27.88 | EDGAR |
| 2026-02-18 | 4 | Verduyn-van Weegen Felice Isabel — Director, 10% owner | Grant/award (A): 358,680 @ $27.88 | EDGAR |
| 2026-02-17 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director RA Capital Healthcare Fund LP — Director RA Capital Nexus Fund III, L.P. — Director Kolchinsky Peter — Director Shah Rajeev M. — Director | Grant/award (A): 35,868 @ $27.88 | EDGAR |
| 2025-12-22 | 4 | Hopfner Robert Lorne — Director, 10% owner | Purchase (P): 1,000 @ $17.35 | EDGAR |
| 2025-12-19 | 4 | Bauer Eugene — Chief Medical Officer, Director | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | Patel Jeegar Pravinkumar — Chief Scientific Officer | Tax withholding (F): 7,513 @ $17.84 | EDGAR |
| 2025-12-11 | 4 | Drew Janice Suzann — EVP, Operations | Tax withholding (F): 5,074 @ $17.84 | EDGAR |
| 2025-12-11 | 4 | Carver Kyle — Chief Financial Officer | Tax withholding (F): 13,290 @ $17.84 | EDGAR |
| 2025-12-11 | 4 | Moss Gregory S. — Chief Business & Legal Officer | Tax withholding (F): 13,624 @ $17.84 | EDGAR |
| 2025-12-11 | 4 | Bauer Eugene — Chief Medical Officer, Director | Tax withholding (F): 1,478 @ $17.84 | EDGAR |
| 2025-12-11 | 4 | Pena Luis C. — President & CEO, Director | Tax withholding (F): 28,138 @ $17.84 | EDGAR |
| 2025-11-12 | 4 | Verduyn-van Weegen Felice Isabel — Director, 10% owner | Conversion (C): 3,367,133 · Purchase (P): 1,562,500 @ $16 · Conversion (C): 15,493,466 (derivative) · Conversion (C): 5,090,000 (derivative) · Conversion (C): 6,585,011 (derivative) | EDGAR |
| 2025-11-12 | 4 | Patel Jeegar Pravinkumar — Chief Scientific Officer | Conversion (C): 3,175 · Conversion (C): 25,000 (derivative) | EDGAR |
| 2025-11-12 | 4 | Drew Janice Suzann — EVP, Operations | Conversion (C): 1,587 · Conversion (C): 12,500 (derivative) | EDGAR |
| 2025-11-12 | 4 | LSP 7 Cooperative UA — 10% owner | Conversion (C): 3,367,133 · Purchase (P): 1,562,500 @ $16 · Conversion (C): 15,493,466 (derivative) · Conversion (C): 5,090,000 (derivative) · Conversion (C): 6,585,011 (derivative) | EDGAR |
| 2025-11-12 | 4 | Carver Kyle — Chief Financial Officer | Conversion (C): 3,175 · Conversion (C): 25,000 (derivative) | EDGAR |
| 2025-11-12 | 4 | Moss Gregory S. — Chief Business & Legal Officer | Conversion (C): 3,175 · Conversion (C): 25,000 (derivative) | EDGAR |
| 2025-11-12 | 4 | Pivotal bioVenture Partners Fund I, L.P. — Director, 10% owner Pivotal bioVenture Partners Fund I G.P., L.P. — Director, 10% owner Pivotal bioVenture Partners Fund I U.G.P. Ltd — Director, 10% owner | Conversion (C): 1,441,032 · Conversion (C): 1,632,441 · Conversion (C): 294,502 · Conversion (C): 7,145,647 (derivative) · Conversion (C): 3,572,816 (derivative) · Conversion (C): 2,582,243 (derivative) · +6 more | EDGAR |
| 2025-11-12 | 4 | Bauer Eugene — Chief Medical Officer, Director | Conversion (C): 25,812 · Conversion (C): 206,355 (derivative) · Conversion (C): 12,500 (derivative) | EDGAR |
| 2025-11-12 | 4 | Pena Luis C. — President & CEO, Director | Conversion (C): 24,225 · Conversion (C): 206,355 (derivative) | EDGAR |
| 2025-11-12 | 4 | Hopfner Robert Lorne — Director, 10% owner | Conversion (C): 3,026 · Conversion (C): 1,441,032 · Conversion (C): 1,632,441 · Conversion (C): 294,502 · Conversion (C): 25,790 (derivative) · Conversion (C): 7,145,647 (derivative) · +8 more | EDGAR |
| 2025-11-12 | 4 | Cohen David E — Director | Conversion (C): 6,056 · Conversion (C): 51,588 (derivative) | EDGAR |
| 2025-11-12 | 4 | RA CAPITAL MANAGEMENT, L.P. — Director, 10% owner | Conversion (C): 1,517,329 · Conversion (C): 691,441 · Purchase (P): 1,157,096 @ $16 · Purchase (P): 92,904 @ $16 · Conversion (C): 12,924,620 (derivative) · Conversion (C): 5,889,699 (derivative) | EDGAR |
| 2025-11-07 | 4 | Patel Jeegar Pravinkumar — Chief Scientific Officer | Grant/award (A): 179,619 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Drew Janice Suzann — EVP, Operations | Grant/award (A): 231,274 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Carver Kyle — Chief Financial Officer | Grant/award (A): 279,408 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Moss Gregory S. — Chief Business & Legal Officer | Grant/award (A): 293,496 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Pena Luis C. — President & CEO, Director | Grant/award (A): 796,841 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Cohen David E — Director | Grant/award (A): 37,960 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | KIRSCH ARTHUR S — Director | Grant/award (A): 37,960 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | MCGRAW BENJAMIN F III — Director | Grant/award (A): 37,960 (derivative) @ $0 | EDGAR |
Recent 8-K events — Evommune, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-02 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-04-13 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition | EDGAR |
| 2026-02-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-10 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EVMN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →